ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents
December 27, 2021A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine. -
Cosentyx®displays a 72 percent reduced arthritis flare risk
November 11, 2021Novartis has announced new analyses from the two-year positive Phase III JUNIPERA study, which demonstrated the treatment response of Cosentyx® (secukinumab)... -
Novartis Presents Positive Results from JUNIPERA Study Supporting Cosentyx as a Treatment in a JIA Population
June 04, 2021Novartis, a leader in rheumatology and immuno-dermatology, announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients ...
Pharma Sources Insight January 2025
